Gyomor- és nyelőcsőrák: vizsgálatok itt: Olaszország
71 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
- Where
- Ancona, Aviano, Brescia, Candiolo, Caserta, Cremona, Florence, Milan, Modena, Naples, Parma, Perugia, Pisa, Ravenna, Reggio Emilia, Rome, San Giovanni Rotondo, Siena, Verona
- Életkor
- 18 év and over
- People
- 570 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07673887 · EU 2025-524557-14-00 - 1/2. fázisTaking peopleBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Where
- Ancona, Candiolo (TO), Meldola (FC), Milan, Misterbianco (CT), Naples, Rozzano
- Életkor
- 18 év and over
- People
- 910 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06324357 - 3. fázisTaking peopleA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Where
- Ancona, Bergamo, Bologna, Brescia, Candiolo, Cremona, Florence, Meldola, Milan, Naples, Pisa, Reggio Emilia, Rome, Siena, Udine, Verona
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT06901531 · EU 2024-519773-19-00 - 2/3. fázisTaking peopleA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Where
- Milan, Naples, Padova, Rome, Turin
- Életkor
- 18 év and over
- People
- 690 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07221149 · EU 2025-523263-37-00 - 2. fázisTaking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Milan, Reggio Emilia, Rome
- Életkor
- 18 év and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - 2. fázisTaking peopleA Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
- Where
- Florence, Milan, Modena, Pisa, Rozzano, Udine, Vicenza
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07069712 · EU 2024-516909-23-00 - 1/2. fázisTaking peopleA Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Where
- Milan
- Életkor
- 18 év and over
- People
- 560 worldwide
- Run by
- Genmab
See details and how to joinNCT03526835 · EU 2024-513627-16-01 - 1/2. fázisTaking peopleEIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
- Where
- Rome
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00 - 1/2. fázisTaking peopleBOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
- Where
- Milan, Naples, Pisa
- Életkor
- 18 év and over
- People
- 220 worldwide
- Run by
- Bold Therapeutics, Inc.
See details and how to joinNCT04421820 · EU 2024-517500-11-00 - 1/2. fázisTaking peopleA Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
- Where
- Milan, Ravenna, Roma, Verona
- Életkor
- 18 év and over
- People
- 235 worldwide
- Run by
- Alentis Therapeutics AG
See details and how to joinNCT06747585 · EU 2024-515459-39-00 - 1/2. fázisTaking peopleSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- Where
- Milan, Padova
- Életkor
- 18 év and over
- People
- 298 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06780111 · EU 2024-514273-22-00 - 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Bergamo, Genova, Naples, Verona
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Candiolo, Milan, Naples, Rome, Rozzano
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 3. fázisTaking peopleA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Where
- Ancona, Castellana Grotte, Genova, Milan, Naples, Padova, Pisa, Rome, Rozzano, Tricase
- Életkor
- 18 év and over
- People
- 510 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06644781 · EU 2023-509630-19-00 - 1. fázisNot yet taking people in OlaszországA phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
- Where
- Milan, Naples
- Életkor
- 18 év and over
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-518348-19-00 - 3. fázisTaking peopleA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
- Where
- Florence, Milan, Monserrato, Naples, Padova, Rozzano, Tricase, Turin
- Életkor
- 18 év and over
- People
- 840 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06764875 · EU 2024-512583-57-00 - 3. fázisTaking peopleSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Where
- Meldola, Milan, Padova, Rozzano, Tricase
- Életkor
- 18 év and over
- People
- 2130 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07431281 · EU 2024-519787-40-00 - 3. fázisTaking peopleA Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Where
- Genoa, Milan, Pisa, Rozzano
- Életkor
- 18 év and over
- People
- 351 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT07043400 · EU 2025-522862-58-00 - 2/3. fázisTaking peopleSymbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- Where
- Milan
- Életkor
- 18 év and over
- People
- 840 worldwide
- Run by
- Pfizer
See details and how to joinNCT07392892 · EU 2025-524717-86-00 - 1/2. fázisTaking peopleA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Where
- Meldola, Milan, Naples, Roma, Rozzano
- Életkor
- 18 év and over
- People
- 1438 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00 - 1/2. fázisTaking peopleA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Where
- Meldola, Milan, Padova, Pisa
- Életkor
- 18 év and over
- People
- 230 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05319730 · EU 2023-505189-26-00 - 1/2. fázisTaking peopleSubstudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- Where
- Meldola, Milan, Pisa
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06469944 · EU 2023-509307-33-00 - 2. fázisTaking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Milan, Naples
- Életkor
- 18 év to 130 év
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - 2. fázisTaking peopleAdjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
- Where
- Milan
- Életkor
- 18 év and over
- People
- 46
- Run by
- Gruppo Oncologico del Nord-Ovest
See details and how to joinNCT06253650 - 1/2. fázisTaking peopleStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Where
- Ancona, Aviano, Meldola, Milan, Naples, Orbassano, Ravenna, Verona
- Életkor
- 18 év and over
- People
- 534 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06128551